| Home | E-Submission | Sitemap | Contact Us |  
Search
Clin Exp Emerg Med Search

CLOSE

Clin Exp Emerg Med > Volume 11(3); 2024 > Article
Maegele: Update on the pathophysiology and management of acute trauma hemorrhage and trauma-induced coagulopathy based upon viscoelastic testing

Abstract

Uncontrolled hemorrhage and trauma-induced coagulopathy (TIC) are the two predominant causes of preventable death after trauma. Early control of bleeding sources and rapid detection, characterization and management of TIC have been associated with improved outcomes. However, recent surveys confirm vast heterogeneity in the clinical diagnosis and management of hemorrhage and TIC from acute trauma, even in advanced trauma centers. In addition, conventional coagulation assays, although still used frequently during the early assessment of bleeding trauma patients, have their limitations. This narrative review highlights the clinical value of rapid point-of-care viscoelastic testing for the early diagnosis and individualized goal-directed therapy in bleeding trauma patients with TIC.

INTRODUCTION

Uncontrolled hemorrhage and trauma-induced coagulopathy (TIC) are the two predominant causes of preventable death after trauma [13]. One of four severely injured patients admitted to the trauma bay is bleeding and has a variable degree of laboratory coagulopathy; early detection, characterization, and management of this condition are associated with improved outcomes [4,5]. Dysfunctional hemostasis in trauma is multifactorial; and the pathophysiology of TIC can be separated into two main categories, acute traumatic coagulopathy and the coagulopathy associated with the lethal triad (resuscitation-associated coagulopathy). These two often exist in varying degrees either independently or together with the potential to become aggravated in a multifactorial sequalae [6]. Also, shock/trauma-induced damage to the endothelium (endotheliopathy) plays a central role in the initiation of TIC. However, much of the data that drive our current concepts continue to be more correlative than causative; robust links are still lacking (Fig. 1) [7].

EMPIRIC THERAPIES

Recent surveys confirm vast heterogeneity in the clinical diagnosis and management of acute trauma hemorrhage and TIC, even in advanced trauma centers [810]. In the acute phase, the clinical strategies follow the damage control resuscitation (DCR) concept. This concept advocates the empirical administration of blood products in predefined ratios [11]. However, optimum ratios are still under debate; no universal standard for the composition of these transfusion packages has yet been established, and storage time may affect the hemostatic competence of these products considerably [12]. Interestingly, the administration of blood products may also lead to coagulopathy in the context of massive bleeding due to anticoagulative factors and the fluid content of blood products [13]. Experimental studies have shown that administration of pRBCs, plasma and platelets in a predefined ratio of 1:1:1 as suggested by the DCR concept [11] results in a hematocrit of approximately 30%, a coagulation factor concentration of approximately 60% and a platelet count of 80×109/L. These are far distant from normal or optimum values [13]. Also, this approach may not be adequate to correct hypoperfusion or coagulopathy during the acute phase of trauma hemorrhage [14]. Additionally, the results from three large-scale randomized controlled clinical trials have recently questioned the empirical and unguided administration of hemostatic agents, e.g., lyopholized plasma, prothrombin complex concentrate and cryoprecipitate, to correct early TIC in bleeding trauma patients [1517]. As a consequence, several European and a few US trauma centers have instituted the concept of goal-directed coagulation therapy (GDCT) based upon results from early point-of-care (POC) viscoelastic testing (VET) [1820].

LIMITATIONS OF CCAs

The coagulation status in severely injured patients is still largely assessed by conventional coagulation assays (CCAs) that have limitations, e.g., prothrombin time ratio (PTr), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and functional fibrinogen level [2124]. These standard tests only capture procoagulant pathways and focus only on the initial phase of the coagulation process until the maximum 5% to 7% of thrombin generation is achieved [22]. Amplification and propagation phases, the phases promoted by the more updated cell-based model of coagulation, are being ignored; and cellular components, especially platelets, are being removed from the samples through preanalytical centrifugation [25].

VISCOELASTIC TESTING

VET enables rapid and comprehensive assessment of the different steps of the coagulation process from initiation to clot formation including dynamics, stability, and sustainability of the evolving blood clot. The technology was first described by Hartert [26], a German physician, in 1948 and is now experiencing a revival for various indications that include trauma [27]. Different VET methods have been developed in which the blood sample is added into a heated cup with a suspended pin connected to a detector system. Either the cup (TEG 5000, Hamonetics Corp; ClotPro, Hamonetics Corp) or the pin (ROTEM, Werfen) rotates at a specific angle to the left and right. Fibrin strands form between the pin and the cup and diminish the rotation angle according to increasing clot strength to produce the typical trace. The technology used in TEG 6s (HemoSonics LLC) and Quantra (HemoSonics LLC) is slightly different; the TEG 6s exposes the blood sample to vibration and measures the resonance frequency induced by the motion of the blood meniscus, and Quantra is based upon ultrasonic estimation of elasticity through resonance to assess the evolution of the viscoelastic properties of the blood clot. Increasing clot stiffness lowers induced vibration and can be displayed as a graph over time. Fully automated and cartridge-based systems, such as ROTEM sigma, TEG 6s, and Quantra, in which blood samples are automatically processed with different activators, as well as the introduction of handling and pipetting aids, have largely eliminated preanalytical operational errors and have facilitated the acceptance and use of VET in daily clinical practice.

REAGENTS FOR VET

A range of different activators and/or inhibitors have been introduced for differential diagnosis of underlying hemostatic disorders in trauma. Like the technological spectrum integrated into the different devices, existing reagents are quite specific and vary considerably in terms of composition, concentration, and activation pathways [28]. Consequently, suggested treatment algorithms may not be transferred between devices without adjustment [29]. Focus is given to the most widespread systems, e.g., rotational thromboelastometry (ROTEM) and thromboelastography (TEG), which provide real-time, POC global information on the dynamics of clot development, stabilization and dissolution that reflect in vivo hemostasis. The most used assays for the two systems in relation to their respective activation pathways and the information derived from these assays are summarized in Table 1; the parameters delivered by the two systems are shown in Fig. 2.

CLINICAL APPLICATION OF VET-BASED GDCT

The concept of GDCT based upon results from early POC VET is intriguing, primarily driven by physiological understanding and promoting individualized care for bleeding trauma patients [19,30,31]. The concept has been shown to reduce bleeding, transfusion of packed RBC (pRBC), plasma, and platelet concentrates, and mortality in mixed surgical populations [32]. Early viscoelastic variables of clot firmness are good predictors of mortality and the need of massive transfusion [33,34]. A recent Cochrane review [32] and a recent meta-analysis [35] demonstrated the effects on the transfusion requirement and the survival benefit with the early use of VET in bleeding patients.
VET is increasingly being recognized for its potential to not only diagnose TIC but also to guide treatment [3639] that augments DCR during the acute care of bleeding trauma patients. The updated European trauma guideline 2023 advocates that monitoring and measures to support coagulation should be initiated immediately upon arrival of the patient to the trauma bay and that routine practice should include the early and repeated monitoring of coagulation using VET. This is a strong grade 1B recommendation [38]. Further resuscitation measures should be continued using a goal-directed approach guided either by standard laboratory coagulation assays and/or POC VET, such as ROTEM (grade 1C recommendation) [38]. A recent survey among surgeons and anesthetists in Germany revealed that more than half already used extended VET, such as ROTEM or TEG, in advanced trauma centers [40].

EMERGING EVIDENCE

Recent evidence has confirmed that VET is highly specific for hyperfibrinolysis, the most lethal and resource-intense phenotype of fibrinolysis in trauma [41], and is more sensitive to detect coagulopathy as compared to CCAs [42]. The introduction of POC ROTEM has altered blood product transfusion practices for major trauma patients [43], leading to faster decision-making and initiation of therapy to correct coagulopathy [42,44], improved functional blood clotting parameters [45,46], and potentially improved safety of transfusion strategies [47,48], to meet the goal of reduced mortality [47,49]. Early goal-directed hemostatic resuscitation of TIC guided by TEG was prospectively explored in a single-center, pragmatic randomized controlled trial in 111 patients, and survival in the TEG group was significantly higher than in the CCA group with less use of plasma and platelets [50].

The RETIC study

In the prospective RETIC (Reversal of Trauma-Induced Coagulopathy) study, an indirect VET benefit was noted; its use was a precondition for demonstrating a survival benefit with targeted coagulation factor supplementation [51]. In this study, trauma patients with coagulopathy identified by abnormal fibrin polymerization or prolonged coagulation time using ROTEM received either fresh frozen plasma (FFP; 15 mL/kg of body weight) or coagulation factor concentrate (CFC; primarily fibrinogen 50 mg/kg of body weight). The study with 100 patients allocated FFP (n=48), or CFC (n=52), was terminated prematurely because of the high proportion of patients in the FFP group requiring rescue therapy. Twenty-three patients (52%) in the FFP group required rescue therapy; only two (4%) in the CFC group required rescue therapy (odds ratio [OR], 25.34; 95% confidence interval [CI], 5.47–240.03; P<0.0001). There was an increased needed for massive transfusion in the FFP group, 13 (30%) in the FFP group versus six (12%) in the CFC group (OR, 3.04; 95% CI, 0.95–10.87; P=0.042). The interim analysis for the predefined endpoint upon premature study termination showed multiple organ failure in 29 patients (66%) in the FFP group and in 25 patients (50%) in the CFC group (OR, 1.92; 95% CI, 0.78–4.86; P=0.15).

The iTACTIC trial

The iTACTIC (implementing Treatment Algorithms for the Correction of Trauma-Induced Coagulopathy) trial was a randomized controlled trial comparing outcomes of severely injured and bleeding trauma patients alive and free of massive transfusion (<10 pRBCs) at 24 hours postinjury. The trial was conducted across six major European trauma centers [52,53]. In total, 396 trauma patients who received empirical massive hemorrhage protocols, augmented by either optimized VET or CCA‐guided interventions, were included. No difference in the intention-to-treat analysis between groups was demonstrated, but there was a strong trend towards increased survival with the use of VET in the prespecified subgroup that was coagulopathic upon arrival in the trauma bay (INR >1.2). This became significant in the subgroup of patients with traumatic brain injury (OR, 2.12; 95% CI, 0.84–5.34). In a single-center study of patients with isolated traumatic brain injury, VET-proven coagulopathy and treatment requiring craniotomy, the rate of hemorrhagic injury progression and need for neurosurgical reintervention were significantly lower when coagulopathy was managed according to VET results [46]. In another single-center study assessing the effects of VET pre- and post-implementation in 201 patients with major hemorrhage, mortality was significantly lower in the post-TEG group at 24 hours (13% vs. 5%, P=0.006) and at 30 days (25% vs. 11%, P=0.002). Also, fewer blood products were wasted [54].

ECONOMIC ASPECTS

Two Italian trauma centers have replaced a former ratio-based transfusion strategy by an early coagulation support (ECS) protocol that includes POC VET and reported a reduction in blood product consumption. The results were statistically significant for plasma (65%) and platelets (52%), and there was a strong but nonsignificant trend toward a reduction in early and 28-day mortality [55]. The overall cost for transfusion and coagulation support including POC VET decreased by 23% after the ECS protocol was implemented in 2013. The clinical and cost-effectiveness of VET devices to assist with diagnosis, management, and monitoring of hemostasis was further assessed across different clinical settings, including TIC cases [56]. Apart from reductions in pRBC, platelet and FFP transfusion in the groups that had used VET devices and in the absence of any differences in clinical outcomes, the use of VET was cost-saving and more effective as compared to CCAs. For the trauma population, the cost-savings owing to VET devices were more substantial, amounting to per-patient savings of 688 GBP for ROTEM and 721 GBP for TEG compared to CCAs. This finding was entirely dependent on material costs, which were slightly higher for ROTEM [56]. Health economic aspects of VET use have also been the focus of other studies, and results have essentially been consistent [47,48,54].

CLINICAL ALGORITHMS

POC VET-based treatment algorithms, including thresholds to initiate GDCT with blood products, coagulation factors and hemostatic agents, have been introduced [27,30,31,36,55,57,58]. Their successful implementation was demonstrated even in initially naïve settings that were unexperienced with the technology [42]. Current and updated national [59] and international trauma and bleeding guidelines [38,39] recommend the local implementation of algorithms and clinical pathways for the management of bleeding trauma patients. These include measures for adherence, quality control, and safety. If key interventions and measures adhered to a formally fixed clinical guideline or algorithm, negative outcomes from trauma, including hemorrhage and mortality and other complication rates, are likely to be reduced [60,61]. However, local algorithms can only consider products, measures and actions that are locally available; not all resources that would compose an optimal clinical pathway may be available. Therefore, adopted algorithms need to reflect local infrastructures and logistics. An example clinical algorithm for early hemostatic control using POC ROTEM test assays is shown in Fig. 3. Specific attention is given to the early and targeted substitution of fibrinogen through cryoprecipitate; fibrinogen is considered as the substrate of the clotting process and the first coagulation factor to reach critical levels during acute blood loss.

LIMITATIONS OF VET

VET has limitations and cannot sufficiently uncover the entire spectrum of coagulation failure. For example, von Willebrand factor deficiencies cannot be detected through VET. Only TEG supplies an assay that allows for the assessment of impaired platelet function through TEG platelet mapping. Although endogenous heparinization is being considered among the key drivers of TIC (Fig. 1), comparisons between INTEM and HEPTEM times have failed to demonstrate any differences in major trauma patients prone to this phenomenon [62].

CONCLUSION

POC VET provides a comprehensive picture of the important aspects of the coagulation process and can rapidly identify underlying hemostatic disorders in the context of severe trauma hemorrhage. Its early application allows for targeted and individualized therapy along the lines of clinically proven algorithms. Several studies have indicated reductions in transfusion requirements with less exposure to harmful blood products, translating into less morbidity. Some researchers and clinicians have linked VET-guided coagulation support to increased survival.

NOTES

Conflicts of interest
The author has received honoraria for speaker’s bureaus, participation in advisory boards, support for conference travels and research projects from Abbott, Astra Zeneca, Baxter, Bayer, CSL Behring, IL-Werfen, LFB Biomedicaments, Octapharma, Portotla Inc, and TEM International. The author has no other conflicts of interest to declare.
Funding
The author received no financial support for this study.
Data availability
Data sharing is not applicable as no new data were created or analyzed in this study.

REFERENCES

1. van Breugel JM, Niemeyer MJ, Houwert RM, Groenwold RH, Leenen LP, van Wessem KJ. Global changes in mortality rates in polytrauma patients admitted to the ICU: a systematic review. World J Emerg Surg 2020; 15:55.
pmid pmc
2. Gruen RL, Jurkovich GJ, McIntyre LK, Foy HM, Maier RV. Patterns of errors contributing to trauma mortality: lessons learned from 2,594 deaths. Ann Surg 2006; 244:371-80.
pmid pmc
3. Teixeira PG, Inaba K, Hadjizacharia P, et al. Preventable or potentially preventable mortality at a mature trauma center. J Trauma 2007; 63:1338-46.
crossref pmid
4. Frohlich M, Mutschler M, Caspers M, et al. Trauma-induced coagulopathy upon emergency room arrival: still a significant problem despite increased awareness and management? Eur J Trauma Emerg Surg 2019; 45:115-24.
crossref pmid pdf
5. Stensballe J, Henriksen HH, Johansson PI. Early haemorrhage control and management of trauma-induced coagulopathy: the importance of goal-directed therapy. Curr Opin Crit Care 2017; 23:503-10.
crossref pmid
6. Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood 2016; 128:1043-9.
crossref pmid pmc pdf
7. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers 2021; 7:30.
crossref pmid pmc pdf
8. Schafer N, Driessen A, Frohlich M, Sturmer EK, Maegele M; TACTIC partners. Diversity in clinical management and protocols for the treatment of major bleeding trauma patients across European level I Trauma Centres. Scand J Trauma Resusc Emerg Med 2015; 23:74.
pmid pmc
9. Fuller G, Bouamra O, Woodford M, et al. Recent massive blood transfusion practice in England and Wales: view from a trauma registry. Emerg Med J 2012; 29:118-23.
crossref pmid
10. Etchill E, Sperry J, Zuckerbraun B, et al. The confusion continues: results from an American Association for the Surgery of Trauma survey on massive transfusion practices among United States trauma centers. Transfusion 2016; 56:2478-86.
crossref pmid
11. Briggs A, Askari R. Damage control resuscitation. Int J Surg 2016; 33(Pt B):218-21.
crossref pmid
12. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313:471-82.
pmid pmc
13. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev 2003; 17:223-31.
crossref pmid
14. Khan S, Brohi K, Chana M, et al. Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage. J Trauma Acute Care Surg 2014; 76:561-8.
crossref pmid
15. Bouzat P, Charbit J, Abback PS, et al. Efficacy and safety of early administration of 4-factor prothrombin complex concentrate in patients with trauma at risk of massive transfusion: the PROCOAG randomized clinical trial. JAMA 2023; 329:1367-75.
pmid pmc
16. Curry N, Davenport R, Lucas J, et al. The CRYOSTAT2 trial: the rationale and study protocol for a multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol activation. Transfus Med 2023; 33:123-31.
pmid
17. Crombie N, Doughty HA, Bishop JR, et al. Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol 2022; 9:e250-61.
crossref pmid pmc
18. Schochl H, Maegele M, Voelckel W. Fixed ratio versus goal-directed therapy in trauma. Curr Opin Anaesthesiol 2016; 29:234-44.
crossref pmid
19. Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski SR, Holcomb JB. How I treat patients with massive hemorrhage. Blood 2014; 124:3052-8.
crossref pmid pdf
20. Maegele M, Nardi G, Schochl H. Hemotherapy algorithm for the management of trauma-induced coagulopathy: the German and European perspective. Curr Opin Anaesthesiol 2017; 30:257-64.
pmid
21. Davenport R, Manson J, De'Ath H, et al. Functional definition and characterization of acute traumatic coagulopathy. Crit Care Med 2011; 39:2652-8.
crossref pmid pmc
22. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1:1504-14.
crossref pmid
23. Haas T, Fries D, Tanaka KA, Asmis L, Curry NS, Schochl H. Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: is there any evidence? Br J Anaesth 2015; 114:217-24.
crossref pmid
24. Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med 2014; 34:453-77.
pmid
25. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85:958-65.
crossref pmid
26. Hartert H. Thrombelastography, a method for physical analysis of blood coagulation. Z Gesamte Exp Med 1951; 117:189-203.
crossref pmid pdf
27. Gorlinger K, Perez-Ferrer A, Dirkmann D, et al. The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management. Korean J Anesthesiol 2019; 72:297-322.
crossref pmid pmc pdf
28. Volod O, Bunch CM, Zackariya N, et al. Viscoelastic hemostatic assays: a primer on legacy and new generation devices. J Clin Med 2022; 11:860.
pmid pmc
29. Hagemo JS, Naess PA, Johansson P, et al. Evaluation of TEG(®) and RoTEM(®) inter-changeability in trauma patients. Injury 2013; 44:600-5.
crossref pmid
30. Schochl H, Nienaber U, Maegele M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15:R83.
crossref pmid pmc
31. Schochl H, Maegele M, Solomon C, Gorlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med 2012; 20:15.
crossref pmid pmc
32. Wikkelso A, Wetterslev J, Moller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016; 2016:CD007871.
pmid pmc
33. Schochl H, Cotton B, Inaba K, et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care 2011; 15:R265.
crossref pmid pmc
34. Ives C, Inaba K, Branco BC, et al. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg 2012; 215:496-502.
crossref pmid
35. Bugaev N, Como JJ, Golani G, et al. Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2020; 89:999-1017.
crossref pmid
36. Inaba K, Rizoli S, Veigas PV, et al. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: report of the panel. J Trauma Acute Care Surg 2015; 78:1220-9.
pmid
37. Wirtz MR, Baumann HM, Klinkspoor JH, Goslings JC, Juffermans NP. Viscoelastic testing in trauma. Semin Thromb Hemost 2017; 43:375-85.
crossref pmid
38. Rossaint R, Afshari A, Bouillon B, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care 2023; 27:80.
crossref pmid pmc pdf
39. Kietaibl S, Ahmed A, Afshari A, et al. Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022. Eur J Anaesthesiol 2023; 40:226-304.
pmid
40. Karl V, Schafer N, Maegele M. Infrastructure, logistics and clinical practice management of acute trauma hemorrhage and coagulopathy: a survey across German trauma centers. Eur J Trauma Emerg Surg 2022; 48:4461-72.
crossref pmid pdf
41. Taylor JR, Fox EE, Holcomb JB, et al. The hyperfibrinolytic phenotype is the most lethal and resource intense presentation of fibrinolysis in massive transfusion patients. J Trauma Acute Care Surg 2018; 84:25-30.
crossref pmid pmc
42. Gratz J, Guting H, Thorn S, et al. Protocolised thromboelastometric-guided haemostatic management in patients with traumatic brain injury: a pilot study. Anaesthesia 2019; 74:883-90.
crossref pmid pdf
43. Campbell D, Wake E, Walters K, et al. Implementation of point-of-care ROTEM® into a trauma major haemorrhage protocol: a before and after study. Emerg Med Australas 2021; 33:457-64.
pmid
44. Blayney A, McCullough J, Wake E, et al. Substitution of ROTEM FIBTEM A5 for A10 in trauma: an observational study building a case for more rapid analysis of coagulopathy. Eur J Trauma Emerg Surg 2022; 48:1077-84.
crossref pmid pdf
45. Ponschab M, Voelckel W, Pavelka M, Schlimp CJ, Schochl H. Effect of coagulation factor concentrate administration on ROTEM® parameters in major trauma. Scand J Trauma Resusc Emerg Med 2015; 23:84.
crossref pmid pmc
46. Rimaitis M, Bilskiene D, Tamosuitis T, Vilcinis R, Rimaitis K, Macas A. Implementation of thromboelastometry for coagulation management in isolated traumatic brain injury patients undergoing craniotomy. Med Sci Monit 2020; 26:e922879.
crossref pmid pmc
47. Dhara S, Moore EE, Yaffe MB, Moore HB, Barrett CD. Modern management of bleeding, clotting, and coagulopathy in trauma patients: what is the role of viscoelastic assays? Curr Trauma Rep 2020; 6:69-81.
crossref pmid pmc pdf
48. Bainbridge FJ, Sinha R, Tocchetti R, et al. Introduction of point-of-care ROTEM testing in the emergency department of an Australian level 1 trauma centre and its effect on blood product use. Emerg Med Australas 2021; 33:893-9.
pmid
49. Lammers DT, Marenco CW, Morte KR, Bingham JR, Martin MJ, Eckert MJ. Viscoelastic testing in combat resuscitation: is it time for a new standard? J Trauma Acute Care Surg 2020; 89:145-52.
crossref pmid
50. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 2016; 263:1051-9.
pmid
51. Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4:e258-71.
crossref pmid
52. Baksaas-Aasen K, Gall L, Eaglestone S, et al. iTACTIC: implementing Treatment Algorithms for the Correction of Trauma-Induced Coagulopathy. Study protocol for a multicentre, randomised controlled trial. Trials 2017; 18:486.
crossref pmid pmc pdf
53. Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med 2021; 47:49-59.
crossref pmid pdf
54. Cochrane C, Chinna S, Um JY, et al. Site-of-care viscoelastic assay in major trauma improves outcomes and is cost neutral compared with standard coagulation tests. Diagnostics (Basel) 2020; 10:486.
crossref pmid pmc
55. Nardi G, Agostini V, Rondinelli B, et al. Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. Crit Care 2015; 19:83.
crossref pmid pmc pdf
56. Whiting P, Al M, Westwood M, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015; 19:1-228; v-vi.
crossref pdf
57. Einersen PM, Moore EE, Chapman MP, et al. Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion. J Trauma Acute Care Surg 2017; 82:114-9.
crossref pmid pmc
58. Stettler GR, Moore EE, Nunns GR, et al. Rotational thromboelastometry thresholds for patients at risk for massive transfusion. J Surg Res 2018; 228:154-9.
crossref pmid pmc
59. Deutsche Gesellschaft für Unfallchirurgie (DGU). [S3 guidelines for polytrauma/severely injured treatment (AWMF registration number 187-023)] [Internet]. Version 4.0. DGU; 2022 [cited 2024 Jan 10]. Available from: https://www.awmf.org/leitlinien/detail/ll/187-023.html.

60. Shafi S, Barnes SA, Rayan N, et al. Compliance with recommended care at trauma centers: association with patient outcomes. J Am Coll Surg 2014; 219:189-98.
crossref pmid
61. Rice TW, Morris S, Tortella BJ, Wheeler AP, Christensen MC. Deviations from evidence-based clinical management guidelines increase mortality in critically injured trauma patients*. Crit Care Med 2012; 40:778-86.
crossref pmid
62. Zipperle J, Oberladstatter D, Weichselbaum N, et al. Thromboelastometry fails to detect autoheparinization after major trauma and hemorrhagic shock. J Trauma Acute Care Surg 2022; 92:535-41.
crossref pmid

Fig. 1.
Current concept of the pathophysiology underlying trauma-induced coagulopathy. Although several hypotheses have been proposed, there is agreement that trauma/tissue injury and shock (hypoperfusion) synergistically trigger the activation of the endothelium with several downstream cascades. Iatrogenic resuscitation may initiate the lethal triad resulting in resuscitation-associated coagulopathy. SHINE, shock-induced endotheliopathy.
ceem-24-202f1.jpg
Fig. 2.
Viscoelastic test parameters for rotational thromboelastometry (ROTEM; Werfen) and thromboelastography (TEG; Hamonetics Corp). Both devices deliver comparable parameter results in seconds and millimeters but are labelled differently. For ROTEM: clot amplitude (CA) after 5 and 10 minutes, clotting time (CT), clot formation time (CFT), lysis index (LY) 30, 45, and 60 minutes after CT, maximum clot firmness (MCF), and maximum lysis (ML). For TEG: CA after 10 minutes, kinetic time (k), LY 30 and 60 minutes after maximum amplitude (MA), MA, and reaction time (r). Viscoelastic testing monitors whole blood hemostasis from clot formation to clot lysis (CL) in a temporal sequence.
ceem-24-202f2.jpg
Fig. 3.
Example of a stepwise, evidence-based clinical treatment alogorithm for early rotational thromboelastometry (ROTEM; Werfen)-guided hemostatic management (test result after 5 minutes of ROTEM operation, A5) in bleeding trauma patients including a recommendation for FIBTEM-guided fibrinogen substitution through the administration of cryoprecipitate using a dose calculator. The ROTEM triggers for the given interventions are based upon consensus from a multidisciplinary conference held in the United States in 2014 [36]. TIC, trauma-induced coagulopathy; ABG, arterial blood gas analysis; TXA, tranexamic acid; EXTEM, extrinsic thromboelastometry; INTEM, intrinsic thromboelas­tometry; FIBTEM, fibrinogen thromboelastometry (platelet-inhibited thromboelastometry); APTEM, aprotinine thromboelastometry (antifibrinolytic thromboelastometry); EX, ROTEM EXTEM assay; FIB, ROTEM FIBTEM assay; ML, maximum lysis; MCF, maximum clot firmness; BW, body weight; CT, clotting time; FFP, fresh frozen plasma.
ceem-24-202f3.jpg
Table 1.
ROTEM/TEG assay nomenclature, activation agents, and assay information
Name Activator Information
Intrinsic assay
 INTEM (ROTEM) Ellagic acid Intrinsic coagulation factors (XII, XI, IX, VIII), heparin-sensitive
 CK (TEG) Kaolin
Extrinsic assay
 EXTEM (ROTEM) Tissue factor Extrinsic coagulation factors (VII)
 CRT (rapid TEG) Kaolin + tissue factor Low-heparin sensitive
Fibrin polymerization assay
 FIBTEM (ROTEM) Cytochalasin Fibrin clot strength Allows for differential diagnosis of a reduced clot amplitude in global tests Sensitive for fibrinolysis
 Functional fibrinogen (TEG) Abciximab
Lysis test
 APTEM (ROTEM) Extrinsically activated test + tranexamic acid Allows for the evaluation of fibrinolytic activity
Heparinase assay
 HEPTEM (ROTEM), CKH (TEG) Intrinsically activated test + heparinase Allows to diagnose/exclude the effect of heparin in intrinsic assays

ROTEM, rotational thromboelastometry; TEG, thromboelastography; INTEM, intrinsic thromboelastometry; CK, citrated kaolin thrombelastography; EXTEM, extrinsic thromboelastometry; CRT, citrated rapid thrombelas­tography; FIBTEM, fibrinogen thromboelastometry (platelet-inhibited thromboelastometry); APTEM, aprotinine thromboelastometry (antifibrinolytic thromboelastometry); HEPTEM, heparine-inhibited thromboelastometry; CKH, citrated kaolin heparinase.

TOOLS
PDF Links  PDF Links
PubReader  PubReader
ePub Link  ePub Link
XML Download  XML Download
Full text via DOI  Full text via DOI
Download Citation  Download Citation
  Print
Share:      
METRICS
0
Crossref
0
Scopus
1,608
View
181
Download
Editorial Office
The Korean Society of Emergency Medicine
101-3104, Brownstone Seoul, 464 Cheongpa-ro, Jung-gu, Seoul 04510, Korea
TEL: +82-31-709-0918   E-mail: office@ceemjournal.org
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © by The Korean Society of Emergency Medicine.                 Developed in M2PI